$A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer$

A multicentre NCRI phase II study of hypofractionated conformal radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer

Bibliographic Details
Main Authors:	Choudhury, A, Swindell, R, Logue, J, Kiltie, A, Clarke, N, Cowan, R
Format:	Conference item
Published:	2010

Similar Items

Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
by: Choudhury, A, et al.
Published: (2011)

Gemcitabine as a Chemoradiosensitiser in Bladder Cancer
by: Kerr, M, et al.
Published: (2012)

Predictive Biomarkers for Gemcitabine as a Chemoradiosensitizer in Bladder Cancer
by: Kerr, M, et al.
Published: (2012)

Treatment of breast and prostate cancer by hypofractionated radiotherapy: potential risks and benefits
by: Ray, KJ, et al.
Published: (2015)

Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits
by: Ray, K, et al.
Published: (2015)

Predicting Erectile Dysfunction after Highly Conformal, Hypofractionated Radiotherapy to the Prostate
by: Kevin Martell, et al.
Published: (2023-05-01)

Hypofractionated radiotherapy part of multimodality treatment in multicentric glioblastoma multiforme: A case report
by: Vanessa Moldoveanu, et al.
Published: (2018-12-01)

Utility of bladder-sparing therapy vs radical cystectomy for muscle-invasive bladder cancer
by: Efstathiou, J, et al.
Published: (2018)

HYPOFRACTIONATED RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY WITH WEEKLY CISPLATIN IN LOCALLY ADVANCED RELATIVELY RADIORESISTENT SUBSITES OF HEAD AND NECK CANCERS
by: K. Baidya, et al.
Published: (2023-03-01)

High MRE11 expression in muscle invasive bladder cancer is predictive of improved cause-specific survival following radical radiotherapy compared to surgery
by: Teo, T, et al.
Published: (2010)

Efficacy and Toxicity of Hypofractionated Palliative Radiotherapy for Breast Cancer Patients with Skin Invasion
by: Talha Maqsood, et al.
Published: (2023-08-01)

Cost Minimization Analysis of Hypofractionated Radiotherapy
by: Hannah L. Yaremko, et al.
Published: (2021-01-01)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
by: Kotwal, S, et al.
Published: (2008)

Comparison of treatment outcome for radical surgery versus radical radiotherapy for invasive bladder cancer treated in a UK specialist treatment centre
by: Kotwal, S, et al.
Published: (2007)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
by: Fabiana Gregucci, et al.
Published: (2021-11-01)

Ultrasound mediated gemcitabine delivery reduces the normal tissue toxicity of chemoradiation therapy in a muscle-invasive bladder cancer model
by: Ruan, J-L, et al.
Published: (2021)

MRE11 variants as predictive markers of radiotherapy response in muscle invasive bladder cancer
by: Teo, M, et al.
Published: (2012)

Ultra-Hypofractionated vs. Moderate Fractionated Whole Breast Three Dimensional Conformal Radiotherapy during the COVID-19 Pandemic
by: Olivera Ivanov, et al.
Published: (2022-05-01)

Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer
by: Janice Ser Huey Tan, et al.
Published: (2024-02-01)

Cardiopulmonary toxicities after hypofractionated radiotherapy in breast cancer
by: Budhi S Yadav
Published: (2022-01-01)

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
by: Choudhury, A, et al.
Published: (2010)

Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
by: Ioannis M. Koukourakis, et al.
Published: (2021-09-01)

Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
by: Hideya Yamazaki, et al.
Published: (2021-12-01)

Improved Outcomes With Dose Escalated Hypofractionated Radiotherapy for Prostate Cancer
by: Mackenzie, J, et al.
Published: (2011)

Hypofractionated Radiotherapy in Gynecologic Malignancies—A Peek into the Upcoming Evidence
by: Razan Amjad, et al.
Published: (2024-01-01)

Hypofractionation Adoption in Prostate Cancer Radiotherapy: Results of an International Survey
by: Ali Sabbagh, et al.
Published: (2023-06-01)

Effect of hypofractionated radiotherapy on lung functions in breast cancer patients
by: Enass A.A. Rezk, et al.
Published: (2023-01-01)

Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: In regard to Kotwal et al. - In reply to Dr. Rosario et al.
by: Kiltie, A, et al.
Published: (2008)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
by: Dalia Elsayed, et al.
Published: (2023-04-01)

Sequential Hypofractionated versus Concurrent Twice-Daily Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis
by: Wei Zhou, et al.
Published: (2022-08-01)

P100 Thyroid dose distribution during hypofractionated radiotherapy for breast cancer
by: M. Ben Rejeb, et al.
Published: (2023-03-01)

P104 Hypofractionated radiotherapy in triple negative breast cancer: Does molecular subtype impact radiotherapy outcomes ?
by: M. Skouri, et al.
Published: (2023-03-01)

NCRI CTRad workshop: translating novel discoveries to and from the clinic
by: Hak, CCW, et al.
Published: (2023)

Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond
by: Febin Antony, et al.
Published: (2024-01-01)

Hypofractionated radiotherapy of patients with glioblastoma: the first experience in Ukraine and prospects view
by: Andrey B. Gryazov, et al.
Published: (2023-03-01)

Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis
by: Dmytro Oliinyk, et al.
Published: (2020-09-01)

The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas
by: Mateusz Jacek Spałek, et al.
Published: (2021-03-01)

Intrafraction Prostate Motion Management for Ultra-Hypofractionated Radiotherapy of Prostate Cancer
by: Christoph Oehler, et al.
Published: (2022-08-01)

Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
by: Chaoyuan Liu, et al.
Published: (2023-06-01)

Reproducibility and geometric accuracy of the fixster system during hypofractionated stereotactic radiotherapy
by: Henriksson Roger, et al.
Published: (2008-05-01)